Overview

An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Allergan
Treatments:
Brimonidine Tartrate